02842nas a2200385   4500000000100000008004100001260001200042653002000054653001100074653002200085653001700107653002600124653002800150100001300178700001500191700001400206700001500220700001700235700001300252700001500265700001600280700001200296700001300308700001400321700001700335700001500352700001500367700001300382245014700395856009500542300001100637490000700648520178700655022001402442       2026                            d  c07/202610aHealth Planning10aAmazon10aNeglected disease10aEpidemiology10aMucosal leishmaniasis10aCutaneous leishmaniasis1 aGuerra J1 ade Sousa D1 aPennini S1 aPinheiro T1 aCavalcante M1 aMendes L1 aCarvalho D1 aBorgonovo F1 aJoão F1 aMaduro I1 aMarques L1 aJustiniano S1 aFerreira J1 aCouceiro K1 aGuerra M00aAdvances and Challenges Regarding American Tegumentary Leishmaniasis in the Amazon: Scientific, Epidemiological and Public Health Perspectives  uhttps://pmc.ncbi.nlm.nih.gov/articles/PMC13427268/pdf/1678-9849-rsbmt-59-s1-e0564-2025.pdf  a1 - 100 v593 a<p>American tegumentary leishmaniasis (ATL) remains a significant public health problem in the Americas, with the Amazon region standing out in Brazil for its high number of cases. This article aimed to present advances in the understanding of epidemiology, diagnosis, treatment and control of ATL in the state of Amazonas over the past decades. This study is a narrative review of scientific studies published in the literature between 2011 and 2025, retrieved from databases such as PubMed and SciELO, as well as public data from the Notifiable Diseases Information System (SINAN), official reports from the Ministry of Health and technical notes from the Amazonas Health Surveillance Foundation. The evolution of disease incidence is reported, highlighting the predominance of Leishmania (Viannia) guyanensis and the environmental factors associated with the increase in cases, such as deforestation and unplanned urbanization. Advances in diagnostic strategies include the expanded use of molecular techniques and the strengthening of the primary healthcare network. Regarding therapy, clinical trials with drugs such as pentamidine, miltefosine, tamoxifen and itraconazole have demonstrated their efficacy in treatment. The review also includes socio-environmental, genetic and experimental studies that have contributed to a better understanding of the disease. It emphasizes the need to establish a priority agenda that includes the use of telemedicine and the institutionalization of collaborative research for therapeutic innovation, integration between research and healthcare services and strategies adapted to the Amazonian context. Regional scientific advances can support more effective control policies and reduce the burden of ATL in this highly endemic setting.</p>  a1678-9849